BertsiasG. K., PamfilC., FanouriakisA., and BoumpasD. T., “Diagnostic criteria for systemic lupus erythematosus: has the time come?,” Nat. Rev. Rheumatol., vol. 9, no. 11, pp. 687–94, 2013.
3.
HuntL. and EmeryP., “Defining populations at risk of rheumatoid arthritis: the first steps to prevention.,” Nat. Rev. Rheumatol., pp. 1–10, 2014.
4.
CastroC. and GourleyM., “Diagnostic Testing and Interpretation of Tests for Autoimmunity,” J Allergy Clin Immunol, vol. 125, no. Suppl 2, pp. S238–S247, 2010.
5.
FaulknerE., AnnemansL., GarrisonL., HelfandM., HoltorfA. P., HornbergerJ., HughesD., LiT., MaloneD., PayneK., SiebertU., TowseA., VeenstraD., and WatkinsJ., “Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: A report of the ISPOR personalized medicine special interest group,” Value Heal., vol. 15, no. 8, pp. 1162–1171, 2012.
6.
MahdiH., FisherB. A., KällbergH., PlantD., MalmströmV., RönnelidJ., CharlesP., DingB., AlfredssonL., PadyukovL., SymmonsD. P. M., VenablesP. J., KlareskogL., andLundbergK., “Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis.,” Nat. Genet., vol. 41, no. 12, pp. 1319–1324, 2009.
7.
KirinoY. and RemmersE. F., “Genetic architectures of seropositive and seronegative rheumatic diseases,” Nat. Rev. Rheumatol., pp. 1–14, 2015.
8.
DengY. and TsaoB. P., “Genetic susceptibility to systemic lupus erythematosus in the genomic era.,” Nat. Rev. Rheumatol., vol. 6, no. 12, pp. 683–692, 2010.
9.
SpearB. B., Heath-ChiozziM., and HuffJ., “Clinical application of pharmacogenetics,” Trends Mol. Med., vol. 7, no. 5, pp. 201–204, 2001.
10.
BranzenK., “Personalized Medicine, A new era for healthcare and industry,” 2013.
